
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf Inc. has demonstrated a strong and positive financial trajectory, highlighted by a 17% year-over-year increase in order entry for 2025, driven by robust demand across both its banking and retail segments. The banking segment specifically reported product revenues of $381 million, a notable 20% increase year-over-year, contributing to total banking revenues of $798 million, which rose 16% quarter-over-quarter and 11% year-over-year. Furthermore, the company achieved positive free cash flow for all four quarters in the fiscal year, with fourth-quarter free cash flow growing 5.4% year-over-year to reach $196 million, positioning the firm for sustainable growth leading into 2026 and beyond.
Bears say
Diebold Nixdorf Inc. is facing a negative outlook due to anticipated declines in backlog and earnings, as a sequential decrease in Q4 results is projected alongside typical seasonal trends. While the company is targeting substantial free cash flow generation from 2025 to 2027, there are significant risks including potential adverse impacts from tariff-related costs and supply chain disruptions, which could further affect financial performance. Moreover, the company’s limited liquidity, highlighted by low average daily trading volume, raises concerns about its overall financial stability and ability to navigate market challenges.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares